Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04602117
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:28.644179+00:00
Published At
2023-11-18T00:00:00+00:00
Record Updated At
2023-11-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-11-18"
protocolSection.identificationModule.nctId
"NCT04602117"
protocolSection.identificationModule.officialTitle
"ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Low (protocolSection.conditionsModule.conditions)
  • SYD-985 (protocolSection.conditionsModule.conditions)
  • SYD985 (protocolSection.conditionsModule.conditions)
  • Vic-trastuzumab Duocarmazine (protocolSection.conditionsModule.conditions)
  • Metastatic Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Gastrointestinal Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Metastatic (protocolSection.conditionsModule.conditions)
  • HER2 Low Breast Cancer (protocolSection.conditionsModule.conditions)
  • GastroEsophageal Cancer (protocolSection.conditionsModule.conditions)
  • Gastroesophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrium Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • HER2-positive Gastric Cancer (protocolSection.conditionsModule.conditions)
  • HER2-positive Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Mutation-Related Tumors (protocolSection.conditionsModule.conditions)
  • HER-2 Protein Overexpression (protocolSection.conditionsModule.conditions)
  • HER2 Low HR Positive (protocolSection.conditionsModule.conditions)
  • HR Positive (protocolSection.conditionsModule.conditions)
  • Hormone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Positive Tumor (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Hormone Receptor Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.